SLDB director Kahn Clare purchases 1,860 shares at $5.34, tripling position to 2,960 shares amid 65.2% decline from 52-week high
Kahn Clare, a SLDB director, purchased 1,860 shares at $5.34 on 2025-03-11, increasing her holdings by 169.1% from 1,100 to 2,960 shares. The transaction occurred at a price 65.2% below the 52-week high of $14.75, though current price of $5.14 now trades slightly below the transaction price. Her prior buy at this ticker on 2024-06-07 showed a 90-day return of +10.9%, demonstrating past timing success at SLDB. However, the company's fundamentals are challenged: revenue stands at $0.00 in the latest quarter, net income is negative $-32,725,000.00, annual revenue contracted 40.6% year-over-year, and the company remained unprofitable over its most recent full fiscal year. The purchase represents a meaningful accumulation by a board member into a distressed-stage biotech with no current revenue generation, warranting detailed scrutiny into what prompted this addition to her position at this juncture.